Successful Completion of Large Pharma Projects
ANGLE successfully completed three large pharma projects with Eisai and AstraZeneca, demonstrating the utility of the Parsortix system in HER2 breast cancer trials and developing assays for DNA Damage Response and Androgen Receptor.
MedTech Collaboration with Myriad Genetics
ANGLE announced its first large medtech collaboration with Myriad Genetics, offering potential for large-scale commercialization of the Parsortix system.
Development of DNA Dual Analysis
A major achievement was the development of the DNA dual analysis, Illumina, end-to-end NGS assay, which identifies twice as many mutations as ctDNA alone.
Accreditation Progress for Clinical Lab
ANGLE is making good progress on accrediting its clinical lab, targeting completion by the end of the year, which would enable offering tests directly for patient management.